Biotech Values

[DewDiligence]

BMY’s Relatlimab_(anti-LAG-3)—>statsig_PFS_as_addend_to_Opdivo_in_1L-melanoma:

https://finance.yahoo.com/news/bristol-myers-squibb-announces-relativity-105900120.html

Bristol Myers Squibb today announced primary results from the Phase 2/3 RELATIVITY-047 (CA224-047) trial evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo (nivolumab) versus Opdivo alone in patients with previously untreated metastatic or unresectable melanoma. The trial met its primary endpoint of progression-free survival (PFS).

Follow up for overall survival, a secondary endpoint, is ongoing. The fixed-dose combination was well-tolerated and there were no new safety signals reported in either the relatlimab and Opdivo combination arm or the Opdivo arm.

These are the first Phase 3 data to be reported from a trial evaluating an anti-LAG-3 antibody.